http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011110736-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0602 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-50 |
| filingDate | 2009-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011110736-A |
| titleOfInvention | METHODS AND COMPOSITIONS FOR TREATING BONE DEFECTS USING PLACENTAL CELLULAR POPULATIONS |
| abstract | 1. A method of treating an individual having multiple myeloma, comprising administering to said individual isolated osteogenic placental adhesive cells (OPAC), wherein said OPAC is derived from chorion and they are adhesive to tissue culture plastic, and wherein said OPAC is negative for CD200 or are CD200dim and positive for CD105 and, where the specified introduction significantly reduces the development of one or more symptoms of the specified multiple myeloma, stops their development or improves them. ! 2. The method according to claim 1, wherein said OPAC are SSEA3 + or SSEA4 +. ! 3. The method of claim 1, wherein said OPACs are SSEA3 + and SSEA4 +. ! 4. The method according to claim 1, in which the indicated OPAC:! express one or more genes at a significantly higher level than the equivalent amount of CD200 + - adhesive placental stem cells, where the specified one or more genes include one or more of BMP3 (bone morphogenetic protein 3), CDH11, COL10A1, COL14A1, COL15A1, DMP1 (dentic matrix of acid phosphoprotein 1), DSPP (dentin sialophosphoprotein), ENAM (enamelin), FGFR2 (fibroblast growth factor receptor 2), MMP10 (matrix metalloprotease 10 (stromelysin 2)), TGFB3 and / or when CD200 + - placental stem cells cultured in a growth medium, as estimated by Ct values from quantitative real-time PCR; ! express one or more genes at a markedly higher level than the equivalent number of CD200 + - adhesive placental stem cells, where the indicated one or more genes include one or more of AMBN (amenoblatin (protein of amelomatrix), BMP2 (bone marrow |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11352639-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2705256-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020050744-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020050743-A1 |
| priorityDate | 2008-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 829.